全文获取类型
收费全文 | 6233篇 |
免费 | 505篇 |
国内免费 | 22篇 |
学科分类
医药卫生 | 6760篇 |
出版年
2023年 | 56篇 |
2022年 | 95篇 |
2021年 | 233篇 |
2020年 | 132篇 |
2019年 | 248篇 |
2018年 | 243篇 |
2017年 | 167篇 |
2016年 | 154篇 |
2015年 | 214篇 |
2014年 | 234篇 |
2013年 | 284篇 |
2012年 | 432篇 |
2011年 | 401篇 |
2010年 | 259篇 |
2009年 | 207篇 |
2008年 | 392篇 |
2007年 | 401篇 |
2006年 | 327篇 |
2005年 | 322篇 |
2004年 | 264篇 |
2003年 | 241篇 |
2002年 | 207篇 |
2001年 | 142篇 |
2000年 | 141篇 |
1999年 | 113篇 |
1998年 | 37篇 |
1997年 | 40篇 |
1996年 | 30篇 |
1995年 | 34篇 |
1994年 | 29篇 |
1993年 | 27篇 |
1992年 | 86篇 |
1991年 | 66篇 |
1990年 | 61篇 |
1989年 | 44篇 |
1988年 | 44篇 |
1987年 | 43篇 |
1986年 | 46篇 |
1985年 | 32篇 |
1984年 | 23篇 |
1983年 | 24篇 |
1982年 | 15篇 |
1981年 | 12篇 |
1979年 | 11篇 |
1976年 | 13篇 |
1974年 | 10篇 |
1972年 | 12篇 |
1970年 | 16篇 |
1969年 | 11篇 |
1968年 | 13篇 |
排序方式: 共有6760条查询结果,搜索用时 0 毫秒
1.
2.
Preadmission testing programs have been developed to recognize and treat medical abnormalities prior to hospitalization, thus reducing preoperative hospital day costs. A preadmission testing program's objectives can be expanded by combining with a discharge planning program. The two programs combined can facilitate discharge planning and patient education prior to hospitalization and coordinate the nursing process. This article will discuss the purposes, organization, and benefits of a preadmission discharge planning program. 相似文献
3.
We conducted a double blind controlled trial in 28 Duchenne muscular dystrophy (DMD) patients with Deflazacort (DF), an oxazoline derivative of prednisolone which reduces its side-effects. Myometric muscle strength measurements, Scott Score and timed tests showed statistically significant improvement for the treated group (P less than 0.05). Side-effects after 9 months of treatment included mild cushingoid appearance in four patients (28%) and moderate in only one (7%), increased appetite in seven (50%), increased body hair in four (28%), irritability and hyperactivity in three (21%). Increased body weight was not prominent and was controlled with dietary measures. No patient had to be withdrawn from medication. More research and long-term follow-up are needed in order to establish the mechanism of improvement and the consequences of long-term steroid administration in DMD. In this regard DF appears as an alternative to prednisone preserving its benefits but with fewer side-effects. 相似文献
4.
5.
6.
As the proportion of racial, ethnic, and cultural minorities in the United States continues to expand, pediatric emergency medicine providers are increasingly likely to encounter cultural and language barriers in practice. This paper reviews a conceptual framework encompassing the decision to seek emergency care, the process of providing such care, and the adherence to treatment plans and follow-up. The ways in which cultural and language barriers can negatively impact each element of this model are discussed in detail. Specific examples include provider ignorance of dangerous folk beliefs, communication barriers secondary to inappropriate interpreter use, and discriminatory assumptions regarding child abuse, pain management, and sexual activity. The practitioner is then provided with concrete recommendations to reduce these negative effects. 相似文献
7.
Berman Brian MD PhD Flores Javier MD † Pariser David MD ‡ Pariser Robert MD ‡ Araujo Tami de MD Ramirez Claudia C. MD 《Dermatologic surgery》2005,31(2):135-138
BACKGROUND Dermatologic procedures often cause some degree of pain. A self-warming patch containing lidocaine and tetracaine (L/T) was developed to provide topical local anesthesia prior to painful procedures.
OBJECTIVES To evaluate the safety and efficacy of a self-warming L/T patch to provide anesthesia in adult patients undergoing minor dermatologic procedures.
METHODS An active or placebo study drug was placed on adults 30 minutes prior to minor dermatologic surgical procedures in a prospectively randomized, double-blinded manner. Subcutaneous lidocaine injection was available during the procedure as a rescue medication if requested by the subject. Immediately following the procedure, the subjects, the investigator, and an independent observer rated pain intensity and adverse events were recorded.
RESULTS Patient-reported pain intensity was significantly lower in the L/T patch group ( p < .001 ). Investigators and an independent observer rated the pain in the L/T patch group to be less than in the placebo patch group ( p = .004 and p < .001 , respectively). Forty-nine percent of patients in the placebo group required rescue subcutaneous lidocaine compared with 22% in the L/T patch study group ( p = .008 ). One patient in the L/T patch group reported a transient moderate burning sensation.
CONCLUSION The self-warming L/T patch was effective in providing clinically useful local anesthesia for minor dermatologic procedures in adult patients.
ZARS, INC., PROVIDED SUPPORT VIA A SPONSORED RESEARCH GRANT TO THE UNIVERSITY OF MIAMI. 相似文献
OBJECTIVES To evaluate the safety and efficacy of a self-warming L/T patch to provide anesthesia in adult patients undergoing minor dermatologic procedures.
METHODS An active or placebo study drug was placed on adults 30 minutes prior to minor dermatologic surgical procedures in a prospectively randomized, double-blinded manner. Subcutaneous lidocaine injection was available during the procedure as a rescue medication if requested by the subject. Immediately following the procedure, the subjects, the investigator, and an independent observer rated pain intensity and adverse events were recorded.
RESULTS Patient-reported pain intensity was significantly lower in the L/T patch group ( p < .001 ). Investigators and an independent observer rated the pain in the L/T patch group to be less than in the placebo patch group ( p = .004 and p < .001 , respectively). Forty-nine percent of patients in the placebo group required rescue subcutaneous lidocaine compared with 22% in the L/T patch study group ( p = .008 ). One patient in the L/T patch group reported a transient moderate burning sensation.
CONCLUSION The self-warming L/T patch was effective in providing clinically useful local anesthesia for minor dermatologic procedures in adult patients.
ZARS, INC., PROVIDED SUPPORT VIA A SPONSORED RESEARCH GRANT TO THE UNIVERSITY OF MIAMI. 相似文献
8.
9.
10.
Friedrich Längle M.D. Thomas Soliman M.D. Nikolaus Neuhold M.D. Gerold Widhalm M.D. Bruno Niederle M.D. Sebastian Roka K. Kaserer M.D. Wolfgang Blauensteiner M.D. Karl Dam M.D. Martin Clodi M.D. Juan Flores M.D. Almute Loidl M.D. Bernhard Schwarzlmüller M.D. Eva Huber M.D. Gerald Jahl Klaus Wamprechtshammer Rudolf Roka M.D. 《World journal of surgery》1994,18(4):583-587
Patients treated for sporadic and hereditary medullary thyroid carcinoma (MTC) have varying rates of persistent disease, recurrence, and survival. The aim of this study was to correlate the immunoreactivity of the monoclonal antibody CD15 (LeuM1) to initial clinical findings and the outcome of treatment. The primary tumors of 75 patients with sporadic MTC, 7 with hereditary disease, and 3 members of MEN 2A families were studied. Of these subjects 74 (87%) showed no or little immunoreactivity (<15% positive cells; score 0) in most tumors. The remaining 13% had surgery for tumors with more than 15% cells with positive staining (score I). There was no correlation between LeuM1 immunoreactivity and sex, age, and type of MTC. There was, however, a significant correlation with the pTNM classification and UICC staging. The prognosis for patients with score 0 was significantly better than score 1 patients. CD15 immunoreactivity appears to be a predictive factor in sporadic and hereditary MTC. Lymph node dissection seems to be more successful in patients with score 0 tumors than in those with score 1 tumors. The question of reoperation in patients with recurrence of disease (especially with biochemical recurrence or persistence) should be discussed on the basis of CD15 immunoreactivity.
Members and institutions are listed in Table 1. 相似文献
Resumen Los pacientes tratados para carcinoma medular, esporádico y hereditario, de la glándula tiroides (CMT) exhiben grandes variaciones en las tasas de enfermedad persistente, recidiva y sobrevida. El propósito del presente estudio fue establecer la correlación entre la inmunorreactividad del anticuerpo CD15 (LeuM1) y los hallazgos clínicos iniciales, así como con el resultado final del tratamiento.Se estudiaron los tumores primarios de 75 pacientes con CMT esporádico, de siete con enfermedad hereditaria y de 3 miembros de familias con síndrome NEM2A.Setenta y cuatro pacientes (87%) exhibieron ninguna o muy baja inmunorreactividad (menos de 15% de células positivas; puntaje 0) en la mayoría de los tumores. El 13% restante fue sometido a cirugía por tumores con más de 15% de las células con coloración positiva (puntaje 1). No se evidenció correlación entre la inmunorreactividad LeuM1 y el sexo, edad o tipo del CMT. Sin embargo, sí apareció una correlación significativa con la clasificiación pTNM y la estadificación de la UICC. El pronóstico de los pacientes con puntaje 0 resultó significativamento mejor que el de los pacientes con puntaje 1.La inmunorreactividad CD15 parece ser un factor de predicción de pronóstico en el CMT esporádico y familiar. La disección ganglionar parece ser más exitosa en pacientes con tumores de puntaje 0 que en los que portan tumores con puntaje 1.El interrogante en cuanto a reoperación en pacientes con recidiva de la enfermedad (especialmente cuando hay recidiva o persistencia bioquímica) debe ser considerada con base en la inmunorreactividad CD15.
Résumé Les taux de maladie persistante, de récidive et de survie chez des patients traités pour cancer médullaire sporadique et héréditaire de la thyroïde (CMT) sont très variables. Le but de cette étude a été de corréler l'immunoréactivité des anticorps monoclonaux CD15 (LeuM1) à des données cliniques initiales et l'évolution finale du traitement des CMT. On a étudié 75 patients ayant un CMT primitif, sept ayant une maladie héréditaire, et trois membres d'une famille MEN 2A. Soixante quatre patients (87%) avaient peu ou pas d'immunoréactivité (moins de 15% de cellules positive: score = 0). Les 13% restants ont eu une chirurgie pour les tumeurs ayant un pourcentage > 15 (score = 1). Il n'y avait aucune corrélation entre l'immunoréactivité LeuM1 et le sexe, l'âge et le type de CMT. Il y avait, en revanche, une corrélation significative entre la classification pTMN et le stage UICC. Le pronostic des patients ayant un score = 0 était significativement meilleur que celui des patients ayant un score = 1. L'immunoréactivité CD15 apparaît comme étant un facteur pronostique des CMT. Le curage lymphatique
Members and institutions are listed in Table 1. 相似文献